Related Experiment Video
Updated: Jan 6, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Identifying novel triazole-containing histone deacetylase 1 antitumor inhibitors through molecular simulations and
Abstract:
Histone deacetylase 1 (HDAC1), a pivotal epigenetic modulator, is critically involved in oncogenesis and serves as a promising target for anticancer drug discovery. In this study, 59 reported HDAC1 inhibitors were utilized to establish robust three-dimensional quantitative structure-activity relationship models for designing novel triazole-containing derivatives with optimized bioactivity and pharmacokinetic profiles. Comparative molecular field analysis ( n = 9, R2 = 0.966, q2 = 0.781) and comparative molecular similarity index analysis ( n = 6, R2 = 0.945; q2 = 0.778) confirmed the predictive reliability of these models. On the basis of the contour maps analysis, the key structural modification sites were determined, and seven promising analogs were reasonably designed. These candidates showed good drug-likeness in ADME/T profiling and formed stable complexes with HDAC1 in molecular simulations, underscoring their promising inhibitory potential. Our study provided a strategic framework for the discovery of HDAC1 drugs and identified promising leads for cancer therapeutics.
Insights
This study developed predictive models for Histone deacetylase 1 (HDAC1) inhibitors, leading to the design of novel triazole compounds with potential anticancer activity. These designed molecules show promising drug-like properties and HDAC1 binding for cancer therapeutics.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Computational Chemistry
Background:
- Histone deacetylase 1 (HDAC1) is a key epigenetic regulator implicated in cancer development.
- HDAC1 is a significant target for novel anticancer drug discovery.
- Developing effective HDAC1 inhibitors requires understanding structure-activity relationships.
Purpose of the Study:
- To establish robust 3D quantitative structure-activity relationship (QSAR) models for HDAC1 inhibitors.
- To design novel triazole-containing HDAC1 inhibitors with improved bioactivity and pharmacokinetic profiles.
- To identify promising lead compounds for cancer therapeutics.
Main Methods:
- Utilized a dataset of 59 reported HDAC1 inhibitors.
- Employed Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA) to build QSAR models.
- Performed contour map analysis to identify key structural modification sites.
- Designed novel analogs based on QSAR model insights.
- Assessed drug-likeness using ADME/T profiling and molecular simulations.
Main Results:
- Developed predictive QSAR models with high statistical reliability (CoMFA: R2=0.966, q2=0.781; CoMSIA: R2=0.945, q2=0.778).
- Identified critical structural features for enhancing HDAC1 inhibitory activity.
- Designed seven novel triazole derivatives exhibiting favorable drug-likeness and predicted stable binding to HDAC1.
- The designed compounds demonstrated potential as effective HDAC1 inhibitors.
Conclusions:
- The established QSAR models provide a reliable framework for designing novel HDAC1 inhibitors.
- The designed triazole derivatives represent promising lead candidates for anticancer drug development.
- This study offers a strategic approach for discovering targeted HDAC1-based cancer therapeutics.
